

ASX RELEASE | OSTEOPORE LIMITED

## OSTEOPORE PRODUCTS ADDED TO THE AUSTRALIAN PROSTHESES LIST

**28 September 2022: Osteopore Limited** (ASX: OSX) (“Osteopore” or the “Company”), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to announce that all products currently listed for use under the Australian Register of Therapeutic Goods (ARTG), will be formally included into the Prostheses List on the 25<sup>th</sup> November 2022.

The Australian Prostheses List identifies implantable devices eligible for reimbursement from all private health insurance funds. This requirement is set out in the Private Health Insurance Act 2007.

Being incorporated into the Prostheses List ensures all Australian citizens with private healthcare coverage can be reimbursed for Osteopore products, with doctors and surgeons being able to choose the best available prostheses for privately insured patients as covered by all the individual healthcare insurance funds.

The list is an essential part of the private health insurance offering, enabling members to receive the best quality healthcare. It is estimated that half of all patients in Australia are treated in the private system, so it is very important that Osteopore implants are featured on the Prostheses List to optimise the Company’s commercial success in Australia.

Osteopore products underwent a rigorous application and review process to be incorporated onto the list, and it is expected to remove barriers to the recommendation of our products to suitable patients in the future, as the implants could potentially reduce the overall healthcare costs of patients.

Executive Chairman, Mark Leong said: “Demand for prostheses has been growing due to population ageing, chronic health conditions and the introduction of new technologies. We are very happy to be included onto the Australian Prostheses List as we can provide our implants to patients with private healthcare insurance at a fully reimbursed price. This could drive more sales in the future.”

*This announcement has been approved for release by the Board of Osteopore.*

For more information, please contact:

**Mark Leong**

Executive Chairman

Osteopore Limited

+65 9011 7009

[Mark\\_Leong@osteopore.com](mailto:Mark_Leong@osteopore.com)

**About Osteopore Limited**

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

### **Forward-Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.